Anzeige
Mehr »
Samstag, 07.02.2026 - Börsentäglich über 12.000 News
Der Shakeout: Silber hat genau das getan, was echte Bullenmärkte immer tun - es hat die Touristen abgeschüttelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ALUN | ISIN: SE0008241491 | Ticker-Symbol: 8F8
Frankfurt
06.02.26 | 15:25
1,978 Euro
+1,75 % +0,034
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SYNACT PHARMA AB Chart 1 Jahr
5-Tage-Chart
SYNACT PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,0152,07513:05

Aktuelle News zur SYNACT PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study163SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment...
► Artikel lesen
30.01.SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency200SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated...
► Artikel lesen
19.01.SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO101SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand...
► Artikel lesen
SYNACT PHARMA Aktie jetzt für 0€ handeln
27.11.25SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB198An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda...
► Artikel lesen
03.11.25SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion185SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients...
► Artikel lesen
31.10.25SynAct Pharma - Approaching a catalyst-rich period334SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid...
► Artikel lesen
30.10.25SynAct Pharma AB: SynAct Pharma publishes Q3 2025 interim results150SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2025. "SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune...
► Artikel lesen
28.10.25SynAct Pharma - Differentiated inflammation resolution approach284SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to...
► Artikel lesen
16.09.25SynAct Pharma AB: SynAct Pharma's CFO Björn Westberg leaves for new leading position152SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company's...
► Artikel lesen
05.09.25SynAct Pharma AB: SynAct appoints Mads Bjerregaard as Chief Business Officer194SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Mads...
► Artikel lesen
20.08.25SynAct Pharma AB: SynAct Pharma publishes Q2 2025 interim results227SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2025. "SynAct continued to strengthen its position during the second quarter, refining its development strategy...
► Artikel lesen
27.05.25SynAct Pharma AB: SynAct Pharma publishes Q1 2025 interim results246SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2025. "SynAct Pharma has a remarkable drug candidate with resomelagon (AP1189). The data gained so far point...
► Artikel lesen
12.05.25SynAct Pharma AB: SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy401SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has provided the issue notification of US patent 12,303,489 with issue date 20 May 2025...
► Artikel lesen
23.04.25SynAct Pharma AB: SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy226SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application US 17/609,849 with claims covering...
► Artikel lesen
11.04.25SynAct Pharma AB: SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue311SynAct Pharma AB ("SynAct Pharma") today announced that the RESOVIR-2 study, an exploratory Phase 2 trial to evaluate the safety and efficacy of the company's lead candidate drug resomelagon (AP1189)...
► Artikel lesen
18.02.25SynAct Pharma AB: SynAct Pharma Year-end Report 2024283SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2024. "SynAct Pharma was running at full speed during the fourth quarter. The team has done a fantastic job ensuring our Phase...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1